Peptency Academy · Section
Research progress
Dated papers, trial registrations and results, and regulator actions on catalog molecules, each with its source.
Research progressAcademyResearch progress5 pages
Newest first
- Regulator action, 14 Sept 2026TGA laboratory test: a product sold as retatrutide held semaglutideOn 14 Sep 2026 Australia's TGA reported that its laboratory found undeclared semaglutide and no retatrutide in a product sold as retatrutide. Sources inside.
- Regulator action, 31 Aug 2026EU editionANSM peptide alert, update of 31 Aug 2026: a police sanitaire decision on a retatrutide productFrance's ANSM updated its alert on peptides sold online on 31 Aug 2026 with a decision of 14 Aug 2026 on a retatrutide product. What it says, with sources.
- Trial result, 28 Aug 2026ARISE-3: registry data posted for a thymosin beta 4 trialOn 28 Aug 2026 ClinicalTrials.gov posted outcome data for ARISE-3 (NCT03937882), a phase 3 randomised trial of thymosin beta 4. Design, status, gaps, sources.
- Publication, 6 Aug 2026Products sold as retatrutide in Australia: content against the labelA 2026 letter reports identity, content and metals tests on three products sold as retatrutide in Australia. What was measured and what is not known, with sources.
- Publication, 30 Jul 2026Impurity profiles of compounded and follow-on semaglutide: a 2026 LC-MS studyA 2026 Pharmaceutical Research study compared LC-MS impurity profiles of follow-on and compounded semaglutide with the originator. Methods, findings, COI, sources.
Research-use information. This library summarises published literature and regulator records. It is not guidance for use, not medical advice, and not a statement that any material is suitable for use in people or animals.